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Abstract: Major advances in the management of patients with chronic lymphocytic leukemia 
(CLL) include an enhanced ability to make an accurate diagnosis and deﬁ  ne clinically meaningful 
prognostic groups, while improving outcome through more effective therapeutic regimens and sup-
portive care. Nevertheless, CLL remains an incurable disorder and new, active agents are needed. 
Bendamustine, a unique cytotoxic agent with structural similarities to both alkylating agents and 
antimetabolites, was recently approved by the US Food and Drug Administration for treatment 
of CLL and rituximab-refractory indolent non-Hodgkin’s lymphoma. In a randomized trial, 
bendamustine was superior to chlorambucil, with comparable toxicity. Combinations with other 
active agents including rituximab and lenalidomide are in development. Nevertheless, numerous 
questions concerning the ideal use of this agent remain to be addressed, including the optimal dose 
and schedule and mechanisms of resistance. The availability of bendamustine provides another 
effective treatment option for patients with lymphoproliferative disorders. Rational development 
of combination regimens will improve the outlook for patients with CLL.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the 
United States (US), with more than 15,000 new cases projected for 2008.1 The median 
age at diagnosis is 72 years and more than half of patients are diagnosed incidentally 
at the time of evaluation for other medical issues.1 Whereas some patients do not 
require treatment at diagnosis and can be managed by watchful waiting, others may 
need treatment for symptomatic or progressive disease.2 For these patients the aim 
of therapy is to prolong survival and improve quality of life as there are no curative 
options. These goals can be achieved by a variety of therapeutic strategies ranging 
from conventional therapies to experimental treatments.
Traditionally, the most frequently used initial systemic therapies have been 
chlorambucil or ﬂ  udarabine. More recently, the availability of effective and well-tolerated 
monoclonal antibodies has substantially altered the therapeutic approaches to these 
patients. The two most widely used have been rituximab and alemtuzumab. Rituximab, 
as a single agent has limited activity in relapsed/refractory CLL; however as an initial 
treatment, response rates of 51% have been reported.3–6 The efﬁ  cacy and tolerability of 
rituximab provided rationale of combining it with other agents. Rituximab, combined 
with ﬂ  udarabine alone or with cyclophosphamide (FR or FCR) has been associated 
with responses in more than 90% of patients, most being complete remissions (CR).7,8 
These regimens also appear to improve survival compared to historical controls.7,9 More 
recently, a randomized study comparing ﬂ  udarabine and cyclophosphamide (FC) to 
FCR showed that FCR treated patients had an increased CR (52% vs 27%, p  0.0001), 
improved progression-free survival (PFS) (2 year: 76.6% vs 62.3%, p  0.0001) and 
a trend towards increased overall survival (OS) (2 year: 91% vs 88%, p 0.18).10 Despite the OncoTargets and Therapy 2009:2 44
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high response rates with rituximab-based combination therapy, 
patients invariably relapse and require additional therapies. 
Moreover, present regimens are associated with signiﬁ  cant 
toxicity, especially in elderly patients.11 As CLL remains 
incurable, there remains a constant need to improve upon the 
current treatment options.
One promising drug is bendamustine, a unique alkylating 
agent, which was ﬁ  rst synthesized in the early 1960s in 
Jena in the former East German Democratic Republic by 
Ozegowski et al12 For over 30 years, bendamustine was used 
in the former German Democratic Republic to treat patients 
with non-Hodgkin’s lymphoma (NHL), CLL, multiple 
myeloma (MM), Hodgkin’s lymphoma, and carcinoma of the 
breast. Following the German reuniﬁ  cation, bendamustine 
was approved in Germany for the treatment of patients with 
indolent NHL, CLL, MM and breast cancer, and many new 
studies were initiated aimed at better deﬁ  ning the value of 
this drug in treating these conditions.
Bendamustine is referred to by the chemical name 
γ-[1-methyl-5-bis-(β-chloroethyl)-amino-benzimidazo-
lyl-(2)]-butyric acid hydrochloride. The structure of 
bendamustine consists of a benzamidazole ring with a 
nitrogen mustard group at position 5 (Figure 1) providing 
structural similarities to both alkylating agents and antime-
tabolites.13 Similar to other alkylating agents, bendamustine 
causes DNA double-strand breaks but these are more exten-
sive and durable than those produced by other alkylating 
agents.14 Bendamustine has also been shown to work by 
activating DNA-damage stress response and intrinsic apop-
tosis, inhibiting mitotic checkpoints, induction of mitotic 
catastrophe, and activating base excisions DNA repair path-
way rather than an alkyltransferase DNA repair mechanism, 
different from other alkylating agents like cyclophosphamide, 
melphalan and chlorambucil.13 Bendamustine exhibits 
incomplete cross-resistance with other alkylating agents 
(eg, cyclophosphamide, melphalan and carmustine) due to 
a substance-speciﬁ  c interaction between bendamustine and 
DNA.14 Moreover, the addition of rituximab in vitro reduces 
the dose of bendamustine required to induce apoptosis in 
ex-vivo B-CLL cells.15,16 This observation provided the 
rationale for the development of clinical studies combining 
these two agents.17–19
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Clinical studies of bendamustine
Several small studies using different dosing schedules 
provided the initial evidence of clinical activity of benda-
mustine in CLL (Table 1).20–22 These studies reported overall 
response rates (ORR) between 65% and 93% with complete 
remission rate (CR) between 7% and 29%.
Dose ﬁ  nding studies
Although bendamustine has been used for over 30 years, 
most of the dosing schedules are empiric, and the optimal 
dose and schedule remains unknown. Several studies have 
been conducted to determine the maximal tolerated dose, 
dose-limiting toxicity and optimal therapeutic dose of benda-
mustine in patients with CLL (Table 1).
Kath et al reported that a 5-day schedule had excessive 
myelotoxicity with a reported rate of leukopenia (grade III/IV) 
of 51% resulting in septic death of 13% of patients.22 This 
study suggested that the 5 day schedule was too toxic for 
many patients.
The German CLL study group (GCLLSG) conducted 
a phase I/II study in 16 patients with relapsed or refractory 
CLL.23 Patients had received a median of 3 prior regimens 
and 50% had previously received ﬂ  udarabine. Dose escalation 
started at 100 mg/m2 intravenously (iv) on days 1 and 2 every 
3 to 4 weeks. Six patients experienced dose-limiting toxici-
ties (DLTs) which led to dose de-escalation; 2 at 100 mg/m2, 
1 at 90 mg/m2, 2 at 80 mg/m2 and 1 out of 7 at 70 mg/m2. The 
maximum tolerated dose (MTD) in this study was 70 mg/m2 
every 4 weeks. Major toxicities included grade III/IV leuko-
penia in 50%, and grade III/IV infection in 43% of patients; 
2 patients died from atypical pneumonia. Despite the dose 
de-escalations, the ORR was 58% (9/16), including 7 of 
12 patients treated at doses of 80 mg/m.2 The median duration 
of response in patients evaluable for response was 42.7 months 
and 43.6 months for the responders. Of the patients that were 
previously treated with ﬂ  udarabine (n = 8) only those who were 
not ﬂ  udarabine refractory responded (n = 4), with 2 CR and 
2 partial remissions (PR). Six of the 8 patients without prior 
ﬂ  udarabine responded with 1 CR.
Lissitchkov et al conducted a phase I/II study of benda-
mustine in ﬂ  udarabine naïve patients with CLL. Dose escala-
tion started at 100 mg/m2 every 3 weeks and in the absence 
of DLT during the ﬁ  rst cycle the dose was to be increased 
by 10 mg/m2 increments.24 The treatment interval had to 
be prolonged to every 28 days to allow for bone marrow 
recovery. Six patients experienced DLTs; 1 at 100 mg/m2, 
2 at 110 mg/m2, while all 3 patients had DLTs at 120 mg/m2. 
DLTs included grade III/IV hyperbilirubinemia, grade IV 
anemia and grade IV thrombocytopenia. Rate of grade III/IV 
leukopenia was 20%. All 6 patients treated at 100 mg/m2 
responded, with 4 CRs and 2 PRs. After a follow up of 
15 months only 1 patient had relapsed and the median dura-
tion of response of patients with CR was 22 months (range 
18–27 months). The recommended dose from this study was 
100 mg/m2 on days 1 and 2 every 28 days.
The tolerability of bendamustine varied between these 
two studies. The MTD of bendamustine in the GCLLSG 
trial was 70 mg/m2 while Lissitchkov et al recommended a 
dose of 100 mg/m2.23,24 The different MTDs between these 
two studies could be explained, in part by the differences in 
their study population that may have increased the likelihood 
of myelosuppression and infection in the GCLLSG study. 
Table 1 Single-agent clinical trials of bendamustine in CLL
Author Phase Regimen Number of patients ORR (CR), % Median time to 
event (months)
Kath 200122 II 70 yrs: 60 mg/m2 
70 yrs: 50 mg/m2 
d 1–5, q 28 d
23; 13 previously 
untreated
65 (26) NR
Aivado 200220 II 100 mg/m2, d 1–2, q 28 d 23 relapsed/refractory 67 (29) TTP 6 (4–19)
Bremer 200221 II 60 mg/m2, d 1–5, q 28 d 15 relapsed/refractory 93 (7) Not reached
Bergmann 200523 I/II 70 mg/m2, d 1–2, q 28 d 16 relapsed/refractory 56 (13) NR
Lissitchkov 200624 I/II 100 mg/m2, d 1–2, q 28 d 15 relapsed/refractory 60 (27) NR
Knauf 200826 III B: 100 mg/m2 d 1–2, q 28 d 
C: 0.8 mg/kg d 1, 15, q 28 d
319 previously 
untreated
B: 67 (NR) 
C: 30 (NR)
PFS (B v C): 
21.5 vs 8.3
Niederle 200825 II B: 100 mg/m2, d 1–2, q 28 d 
F: 25 mg/m2, d 1–5, q 28 d
96 relapsed B: 78 (29) 
F: 65 (10)
PFS (B vs F): 
83 vs 64 weeks
Abbreviations: ORR, overall response rate; CR, complete remission rate;   TTP, time to progression; PFS, progression-free survival; OS, overall survival; D, days; NR, not reported; 
B, bendamustine; C, chlorambucil; F, ﬂ  udarabine.OncoTargets and Therapy 2009:2 46
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The GCLLSG trial included patients who were elderly with 
advanced disease who had been heavily pretreated (upto 
6 prior therapies), and were resistant to either ﬂ  udarabine, 
chlorambucil or both.23 While Lissitchkov et al included 
patients who were ﬂ  udarabine naïve and had received an 
average of 3 prior therapies, explaining in part the better 
tolerability of bendamustine.24
Randomized trial of single-agent 
bendamustine in patients
with relapsed CLL
Bendamustine has been directly compared with ﬂ  udarabine in 
patients with CLL who had relapsed after one prior therapy.25 
In this study, ﬂ  udarabine naïve patients were randomized to 
either bendamustine (100 mg/m2 d 1–2 q 28 days) or ﬂ  uda-
rabine (25 mg/m2 d 1–5 q 28 days) until best response or to a 
maximum of 8 cycles. The primary objective of the study was 
to determine if progression-free survival (PFS) was comparable 
between the two treatment arms. Out of a total of 96 patients 
89 were eligible for an interim analysis (46 patients assigned to 
bendamustine and 43 to ﬂ  udarabine). Baseline characteristics 
including age, Binet stage, bulky disease, and B-symptoms 
were equally matched between the groups. Ninety-ﬁ  ve percent 
of patients had received a chlorambucil-based regimen as 
their initial therapy. About half of the patients received 6 or 
more cycles in either treatment arm. The ORR was 78% (29% 
CR) in the bendamustine arm versus 65% (10% CR) in the 
ﬂ  udarabine arm. After a median follow up of 2 years, median 
PFS was 83 weeks versus 63 weeks (HR 0.93, CI 0.59–1.47) 
with bendamustine and ﬂ  udarabine, respectively. The benda-
mustine arm was associated with a slightly higher incidence 
of hematologic toxicity, but the rate of grade III/IV infections 
was similar, occurring in 15% of the patients in both the arms. 
This study suggested that bendamustine can be considered a 
reasonable alternate to ﬂ  udarabine. However, conﬁ  rmation in 
a larger study is warranted.
Phase III clinical trial in previously 
untreated patients with CLL
Knauf et al conducted a multicenter study, in which they 
randomized 319 previously untreated CLL patients to 
either bendamustine or chlorambucil.26 Bendamustine was 
administered at 100 mg/m2 iv on 2 consecutive days, while 
chlorambucil was given at 0.8 mg/kg orally on days 1 and 15. 
Cycles were repeated every 28 days. Treatment was repeated 
for a maximum of 6 cycles. Primary endpoints of the study 
were ORR and PFS. The secondary endpoints were OS and 
safety.
Median age was 64 years and patients had Binet stage B 
(70%) or C (30%) disease. Treatment was well tolerated with 
mean number of cycles administered being 4.8 (SD ± 1.7) 
with bendamustine and 4.6 (SD ± 1.7) with chlorambucil. 
Most doses were administered on schedule and dose intensity 
was maintained in both groups, 86% with bendamustine and 
96% with chlorambucil. All 319 patients were evaluable 
for efﬁ  cacy analysis, 162 on the bendamustine arm and 157 
on the chlorambucil arm. Response rates were superior for 
bendamustine compared with chlorambucil, ORR 67% versus 
30% (p  0.0001), respectively. After a median follow up 
of 29.2 months, the median PFS was 21.5 months versus 
8.3 months (p  0.0001), for bendamustine and chloram-
bucil, respectively. As of the time of the report, there was 
no difference in overall survival.
Toxicities of bendamustine were predictable and man-
ageable. Grade III/IV neutropenia, thrombocytopenia, and 
anemia were observed more frequently in the bendamustine 
arm (Table 2). Nevertheless, grade III/IV infections were 
uncommon in both groups (7% versus 4% in bendamustine 
versus chlorambucil group, respectively). Non-hematologic 
adverse reactions (any grade) in the bendamustine group 
that occurred with greater than 15% frequency were pyrexia 
(24%), nausea (20%), and vomiting (16%). The most frequent 
adverse reactions leading patients receiving bendamustine 
to withdraw from the study were hypersensitivity (2%) and 
pyrexia (1%).
Based largely on the results of this pivotal study, the US 
Food and Drug Administration (FDA) approved bendamus-
tine for the treatment of CLL.
Bendamustine combination therapy for CLL
Bendamustine has also been investigated in combination 
with other agents (Table 3). In one study, bendamustine 
was evaluated with mitoxantrone in 22 patients.27 In this 
phase I/II study bendamustine was given in escalating doses 
of 80 to 240 mg/m2 per cycle divided over 2 to 3 days, while 
Table 2 Grade 3– 4 hematological toxicities occurring in at least 
5% of patients in the randomized CLL clinical study
Bendamustine (%) Chlorambucil (%)
(n = 150) (n = 141)
Leukopenia 28 3
Neutropenia 43 21
Lymphopenia 47 4
Thrombocytopenia 11 10
Anemia 13 9OncoTargets and Therapy 2009:2 47
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mitoxantrone was administered on day 1 in doses ranging 
from 8 to 10 mg/m2. Treatment was repeated every 29 days 
for up to 6 cycles. Majority of patients received bendamustine 
at either 150 mg/m2 (n = 8) or 240 mg/m2 (n = 6). The ORR 
was 86% with 27% CR. Median time to progression was 
10 months and median over all survival was 39 months. At the 
recommended dose of 150 mg/m2 7 out of the 8 patients had 
grade III/IV neutropenia with two developing infections.
In a pilot phase I/II study, bendamustine was combined 
with mitoxantrone and rituximab (BMR) in 54 patients with 
B-cell malignancies including 21 with CLL.28 Bendamustine 
was given at 80 mg/m2 for 2 days, mitoxantrone 10 mg/m2 
on day 1 and rituximab week 2 through to 5. Cycle 2 was 
started on day 36 and subsequent cycles were delivered 
every 28 days. Treatment was discontinued once a CR or a 
partial response was achieved: 72% of patients received only 
2 cycles of therapy as they achieved a response. Toxicity 
was mainly hematologic in 43% of the all patients, mostly 
experiencing grade III/IV leukopenia and thrombocytopenia. 
CLL patients showed ORR of 95% with 23% CR, remissions 
were lasting with a median time to progression of 17 months. 
At this time in the absence of larger studies, this regimen 
should not be considered outside of clinical trials.
The present dosing of bendamustine with rituximab in 
relapsed or refractory CLL is based on the following mul-
ticenter phase II study (CLL2M) conducted by GCLLSG 
for relapsed or refractory CLL.17 Patients were treated with 
bendamustine at 70 mg/m2 on days 1 and 2, with rituximab 
375 mg/m2 for the ﬁ  rst cycle and 500 mg/m2 for the sub-
sequent cycles, treatment was administered every 28 days 
for a maximum of 6 cycles. In the 81 enrolled patients, the 
median age was 66 years and they had received a median 2 
(range 1–3) prior therapies. After a total of 328 cycles in 
the 81 evaluable patients, 123  grade III toxic events were 
seen, including leukopenia/neutropenia (11.9%), throm-
bocytopenia (9.1%), and anemia (6.1%). Sixteen episodes 
of grade III infections were observed, most were managed 
successfully. However, treatment related mortality occurred 
in 3 (3.7%) patients, all related to infections during neutro-
penia. The reported ORR was 77.4%, with 14.5% CRs in 
62 evaluable patients. Only 3 (4.8%) patients had progressive 
disease. No molecular remissions were achieved in the bone 
marrow, as assessed by 4-color ﬂ  ow cytometry. Difference in 
responses were noted among the various prognostic groups, 
with an ORR of 77.7% (9/7) in patients with ﬂ  udarabine 
refractory disease, 92.3% (12/13) with 11q deletion, 100% 
(8/8) with trisomy 12, 44.4% (4/9) with 17p deletion, and 
74.4% (29/39) in patients with unmutated immunoglobulin 
heavy chain. These results are encouraging but more mature 
results of this study and other trials with this combination 
are needed before this regimen can be recommended as 
routine therapy.
Conclusions
Bendamustine is clearly an effective, well-tolerated drug for 
patients with CLL. It has been approved in the US for CLL 
and rituximab-refractory indolent NHL, and in Germany for 
CLL, NHL and MM.
Currently, a number of active regimens are available for 
the front line treatment of CLL. These include ﬂ  udarabine 
and rituximab with or without cyclophosphamide, and 
alemtuzumab. CLL is a disease of the elderly and some of 
these therapies may not be well tolerated in older patients.11 
A major cause of morbidity and mortality are infections. 
Single agents studies of ﬂ  udarabine have reported an inci-
dence of grade III/IV infections as high as 27%.29,30 In contrast, 
Table 3 Combination therapy trials of bendamustine in CLL
Author Phase Regimen Number of patients ORR (CR), % Median time to 
event (months)
Koppler 200427 I/II B: 80–240 mg/m2 over 2–3 days 
M: 8–10 mg/m2 d 1
22 relapsed/refractory 86 (27) TTP: 10 (4–22)
Weide 200428 I/II B: 80 mg/m2 d 1–2, 
M: 10 mg/m2 d 1; 
cycle 2 d 36 then q 28 d 
R: 375 mg/m2 wk 2–5
21 relapsed/refractory 95 (23) TTP: 17 (1–34+)
Fischer 200817 II B: 70 mg/m2 d 1–2 
R: 375 mg/m2 for cycle 1 then 
500 mg/m2 for 
subsequent cycles
81 relapsed/refractory 77.4 (14.5) NR
Abbreviations: ORR, overall response rate; CR, complete remission rate;   TTP, time to progression; PFS, progression free survival; OS, overall survival; D, days; NR, not reported; 
B, bendamustine; R, rituximab; M, mitoxantrone; C, chlorambucil; F, ﬂ  udarabine.OncoTargets and Therapy 2009:2 48
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in the phase III trial with bendamustine, the rate of grade III/IV 
infections were only 7%.26 Patients receiving therapy with 
ﬂ  udarabine are also at risk of developing autoimmune phe-
nomenon, while bendamustine does not seem to be associated 
with that risk. Interestingly, in one study Aivado et al noted 
that with bendamustine, autoimmune phenomenon resolved 
in 2 out of 2 patients, while no further episodes occurred in 
7 patients with a prior history autoimmune disorder.20 There-
fore, for patients not suitable for ﬂ  udarabine-based therapies, 
either because of infectious risk, autoimmune phenomenon, 
or other factors, single agent bendamustine seems to provide 
a more tolerable alternative. Bendamustine also provides a 
reasonable option for patients not considered appropriate 
candidates for alemtuzumab either because of recurrent infec-
tions or bulky lymphadenopathy. In elderly patients, where 
clinicians tend to consider chlorambucil as initial therapy, 
the superiority of bendamustine over chlorambucil with no 
signiﬁ  cant difference in the rate of grade III/IV infections, 
provides further rationale for its use.26
The greatest potential of bendamustine lies in combina-
tion therapy. Early results have shown good efﬁ  cacy with a 
tolerable toxicity proﬁ  le of bendamustine with rituximab in 
relapsed or refractory CLL.17 GCLLSG is currently testing 
bendamustine and rituximab in the frontline setting and 
initiating a comparative study of bendamustine and rituximab 
with ﬂ  udarabine, cyclophosphamide and rituximab in previ-
ously untreated patients.
Other active agents of interest in CLL include lenalido-
mide and ﬂ  avopiridol. Lenalidomide is currently approved 
in the US for patients with myelodysplastic syndrome with 
5q- and after ﬁ  rst line therapy in MM. It has shown good 
efﬁ  cacy in CLL with ORRs of 32%–47% in the relapsed 
or refractory setting.31,32 Flavopiridol also has encouraging 
activity in CLL, with an ORR of 45% in relapsed or refractory 
patients.33 More encouragingly, these agents have also shown 
responses in CLL patients with poor-risk features. Additional 
clinical trials of these agents with bendamustine may improve 
outcome of patients with poor-risk CLL. Therefore, to further 
evaluate this potential, bendamustine is currently being 
combined with lenalidomide (Cheson pers comm.).
Clinicians need to be familiar with the dosing and 
toxicities of bendamustine. Based on the results of 
the phase III trial and two phase I/II studies, at this 
time the recommended single agent dose of benda-
mustine for previously untreated CLL is 100 mg/m² 
iv on days 1 and 2 every 28 days.26 While for relapsed 
patients, the GCLLSG recommends a dose of 70 mg/m2 
iv for 2 days every 28 days.23 The dose for the combination 
of bendamustine with rituximab has been suggested 
at 70 mg/m2 in previously treated and 90 mg/m2 in the 
frontline setting.17 Major toxicity of bendamustine is 
myelosuppression, but its degree and duration needs to 
be better deﬁ  ned. Encouragingly, bendamustine does not 
appear to be associated with a greater risk of serious infec-
tions when compared with agents such as chlorambucil. 
Nausea and vomiting are common but easily manageable, 
while an occasional patient may experience an allergic 
reaction. Presently, it is recommended to use caution 
when used in patients with mild to moderate renal or 
hepatic impairment. As bendamustine has not been tested 
in patients with creatinine clearance 40 mL/min or 
with AST or ALT  2.5 times or bilirubin 3 times the 
upper limits of normal, it should be avoided in this patient 
population until data demonstrate safety in such patients. 
As this drug is used more widely, uncommon toxicities 
may be encountered and should be reported.
Despite extensive use with bendamustine for over 
40 years, a number of questions remain unanswered. For 
example, the optimal dose and schedule have yet to be 
determined. The dose of bendamustine as a single agent 
and in combination with other agents such as rituximab has 
been empiric. For example, the approved dose for ritux-
imab-refractory follicular lymphomas is 120 mg/m2 days 1 
and 2 on an every 3 week schedule, while it is 90 mg/m2 in 
combination with rituximab, given every 4 weeks. However, 
in CLL the recommended dose is 100 mg/m2 as a single 
agent in the up-front setting, and 70 mg/m2 in combination 
with rituximab. Present data seem to suggest efﬁ  cacy of 
bendamustine in patients who have failed alkylators and/
or ﬂ  udarabine.20,23,25 What is unknown is the efﬁ  cacy and 
tolerability of these drugs after exposure to bendamustine. 
Further studies are needed to better characterize its role 
in relapsed patients. In order to change current treatment 
practices additional clinical trials are needed to determine 
the efﬁ  cacy of bendamustine, possibly in combination with 
more standard front line treatments, similar to the one being 
initiated by the GCLLSG.
In summary, bendamustine provides an effective and 
well-tolerated option for the treatment of patients with CLL. 
Further rational development of this agent will improve 
the outcome of patients with this common hematologic 
malignancy.
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